Nextcell Pharma Ab
- Country
- 🇩🇰Denmark
- Ownership
- Public
- Established
- 2014-03-19
- Employees
- 11
- Market Cap
- -
Clinical Trials
4
Trial Phases
1 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials
Treatment of Respiratory Complications Associated With COVID19,Influenza ,Metapneumovirus,RSV Infection Using ProTrans®
- Conditions
- COVID-19 Acute Respiratory Distress SyndromeRespiratory Syncytial Virus (RSV)Influenza AMetapneumovirus Pneumonia
- Interventions
- Biological: ProTrans®
- First Posted Date
- 2021-05-21
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- NextCell Pharma Ab
- Target Recruit Count
- 9
- Registration Number
- NCT04896853
- Locations
- 🇸🇪
Department of Cardiology, Respiratory medicine and Physiology, Örebro University Hospital, Örebro, Sweden
Wharton´s Jelly Derived Mesenchymal Stromal Cell Repeated Treatment of Adult Patients Diagnosed with Type I Diabetes
- First Posted Date
- 2019-06-04
- Last Posted Date
- 2025-03-07
- Lead Sponsor
- NextCell Pharma Ab
- Target Recruit Count
- 15
- Registration Number
- NCT03973827
- Locations
- 🇸🇪
Karolinska Trial Alliance, Fas 1 enheten, Karolinska Universitetssjukhuset Huddinge, Huddinge, Sweden
Wharton´s Jelly Derived Mesenchymal Stromal Cell Treatment of Adult Patients Diagnosed With Type I Diabetes
- Conditions
- Type1 Diabetes Mellitus
- Interventions
- Drug: Placebos
- First Posted Date
- 2018-01-23
- Last Posted Date
- 2023-04-03
- Lead Sponsor
- NextCell Pharma Ab
- Target Recruit Count
- 24
- Registration Number
- NCT03406585
- Locations
- 🇸🇪
Karolinska Trial Alliance, Fas 1 enheten, Karolinska Universitetssjukhuset Huddinge, Stockholm, Sweden
News
NextCell Pharma Secures US Patent for MSC Prediction Algorithm to Personalize Cell Therapy
NextCell Pharma AB received a US patent for its MSC Prediction Algorithm, which predicts the efficacy of mesenchymal stromal cell therapy in individual patients with autoimmune diseases.
Diamyd Medical Secures Additional Funding for Phase III Type 1 Diabetes Trial with Fast Track Designation
Diamyd Medical has raised approximately SEK 267 million ($25.5 million) through rights issues and a directed issue, receiving an additional SEK 1.6 million beyond previously announced figures.